Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05821088 · ClinicalTrials.gov registry record · Phase 2

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

A Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified and Recurrent Grade 3b Follicular Lymphoma, sponsored by David Bond, MD.

Recruiting
Registry status
Phase 2
Development phase
37
Enrollment target
1
Study location

NCT05821088: Recruiting Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified and Recurrent Grade 3b Follicular Lymphoma, sponsored by David Bond, MD.

NCT05821088 is a Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified and Recurrent Grade 3b Follicular Lymphoma that is actively recruiting participants, run by David Bond, MD. The registered enrollment target is 37 participants, roughly in line with the 38-participant average among 8 other Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05821088, a Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified and Recurrent Grade 3b Follicular Lymphoma, is actively recruiting participants, sponsored by David Bond, MD.

RECRUITING
Registry status
Phase 2
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide may have antineoplastic activity which may help block the formation of growths that may become cancer. Drugs used in chemotherapy, such as carboplatin, etoposide and ifosfamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tafasitamab and lenalidomide followed by ICE may be a better treatment for patients with relapsed or refractory large B-cell lymphomas.

Primary Outcome

Will be defined as patients who have achieved CR after two cycles (tafasitamab and lenalidomide) or four cycles as assessed by positron emission tomography (PET) imaging.

Conditions Studied

Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent Grade 3b Follicular Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Interventions

  • DRUG Carboplatin
  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy
  • DRUG Etoposide

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2023-06-29
Est. Completion 2026-12-31
Phase Phase 2
David Bond, MD

4 total trials

What NCT05821088 shows while recruiting

NCT05821088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, roughly in line with the 38-participant average among 8 other Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials with a reported enrollment target.

The record links to 10 conditions, with Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT05821088 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05821088 about?

NCT05821088 is a clinical study titled "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma". This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refr...

What is the current status of trial NCT05821088?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2023-06-29. Estimated completion is 2026-12-31.

What conditions does trial NCT05821088 study?

This clinical trial studies the following conditions: Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements.

What interventions are being tested in trial NCT05821088?

The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Etoposide (DRUG).

Who is sponsoring clinical trial NCT05821088?

This trial is sponsored by David Bond, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05821088 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05821088's enrollment target sits among peer trials

37 3rd of 8 higher than 6 of 8 other Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05821088

Source: ClinicalTrials.gov NCT05821088, the US trial registry maintained by the National Library of Medicine. NCT05821088 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.